1632118-69-4

Basic information

• Product Name: BAR 501
• Synonyms: BAR 501;BAR501, 98%, a potent and selective agonist of GPBAR1
• CAS NO: 1632118-69-4
• Molecular Formula: C26H46O3
• Molecular Weight: 406.64164
• EINECS: -0
• Mol File: 1632118-69-4.mol

Chemical Properties

• Boiling Point: 527.6±25.0 °C(Predicted)
• Appearance: /
• Density: 1.047±0.06 g/cm3(Predicted)
• PKA: 14.82±0.70(Predicted)
• CAS DataBase Reference: BAR 501(CAS DataBase Reference)
• NIST Chemistry Reference: BAR 501(1632118-69-4)
• EPA Substance Registry System: BAR 501(1632118-69-4)

Safety Data

• Hazardous Substances Data: 1632118-69-4(Hazardous Substances Data)

Usage

Uses

Used in Agriculture:
BAR 501 is used as a fungicide for the control of various fungal diseases in cereal crops. It is particularly effective against leaf rust, septoria tritici, and tan spot, ensuring the protection and health of the crops.
Used in Wheat Production:
BAR 501 is used as a protective agent in wheat cultivation to control fungal infections that can lead to reduced yields and crop quality.
Used in Barley Production:
In barley farming, BAR 501 is used as a disease management tool to prevent the spread of fungal pathogens, thus maintaining the health and productivity of the crop.
Used in Rye Production:
BAR 501 is utilized in rye cultivation as a fungicidal treatment to combat fungal diseases, ensuring the crop's resistance and overall health.
It is crucial to adhere to label instructions and safety precautions when applying BAR 501 to minimize any potential environmental impact and to ensure the proper and effective use of the chemical.

Upstream product

• 951694-73-8 methyl (4R)-4-((3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate 
• 863239-59-2 3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-carboxylic acid methyl ester 
• 462122-38-9 3α-hydroxy-6α-ethyl-7-keto-5β-cholanic acid methyl ester 
• 10538-59-7 7-ketolithocholic methyl ester 
• 4651-67-6 7-Ketolithocholic acid 
• 10452-65-0 methyl 3α-acetoxy-7-oxo-5β-cholan-24-oate 

Relevant articles and documents

Synthesis and characterization of new impurities in obeticholic acid

Novel and efficient synthetic strategies are developed for the first synthesis of two new impurities found in obeticholic acid. The synthetic routes to the impurities are designed without column purification using 4-nitrobenzoyl chloride as a selective pr

TETRAZOLE DERIVATIVES OF BILE ACIDS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF

The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.

CHOLANE DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF FXR AND TGR5/GPBAR1 MEDIATED DISEASES

13073PTWO 56 ABSTRACT The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases. 5

Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands

Nuclear and G-protein coupled receptors are considered major targets for drug discovery. FXR and GP-BAR1, two bile acid-activated receptors, have gained increasing consideration as druggable receptors. Because endogenous bile acids often target both receptor families, the development of selective ligands has been proven difficult, exposing patients to side effects linked to an unwanted activation of one of the two receptors. In the present study, we describe a novel library of semisynthetic bile acid derivatives obtained by modifications on the cholane scaffold. The pharmacological characterization of this library led to the discovery of 7α-hydroxy-5β-cholan-24-sulfate (7), 6β-ethyl-3α,7β-dihydroxy-5β-cholan-24-ol (EUDCOH, 26), and 6α-ethyl-3α, 7α-dihydroxy-24-nor-5β-cholan-23-ol (NorECDCOH, 30) as novel ligands for FXR and GP-BAR1 that might hold utility in the treatment of FXR and GP-BAR1 mediated disorders.

Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors

Bile acids exert genomic and nongenomic effects by interacting with membrane G-protein-coupled receptors, including the bile acid receptor GP-BAR1, and nuclear receptors, such as the farnesoid X receptor (FXR). These receptors regulate overlapping metabolic functions; thus, GP-BAR1/FXR dual agonists, by enhancing the biological response, represent an innovative strategy for the treatment of enteroendocrine disorders. Here, we report the design, total synthesis, and in vitro/in vivo pharmacological evaluation of a new generation of dual bile acid receptor agonists, with the most potent compound, 19, showing promising pharmacological profiles. We show that compound 19 activates GP-BAR1, FXR, and FXR regulated genes in the liver, increases the intracellular concentration of cAMP, and stimulates the release of the potent insulinotropic hormone GLP-1, resulting in a promising drug candidate for the treatment of metabolic disorders. We also elucidate the binding mode of the most potent dual agonists in the two receptors through a series of computations providing the molecular basis for dual GP-BAR1/FXR agonism.